Advanced Oncotherapy - Director/PDMR Shareholding

Advanced Oncotherapy

30/12/2022 09:24

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221230:nRSd3357La&default-theme=true

RNS Number : 3357L  Advanced Oncotherapy PLC  30 December 2022

30 December 2022

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

Director/PDMR Shareholding

 

Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation
proton therapy system for cancer treatment, announces that, on 29 December
2022, Michael Bradfield, Non-Executive Director, purchased a total of 500,000
ordinary shares of 25p each in the Company ("Ordinary Shares") at an average
price of 13.165 pence per share. Following this purchase, Michael Bradfield
has a total beneficial interest in 8,354,240 Ordinary Shares equivalent to
1.55 per cent of the Company's issued share capital.

 

Further details and the information required in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014
are set out at the end of this announcement.

- ENDS -

 

 

 Advanced Oncotherapy plc                           www.avoplc.com (http://www.avoplc.com)
 Dr Michael Sinclair, Executive Chairman            Tel: +44 (0) 20 3617 8728
 Nicolas Serandour, CEO

 Allenby Capital Limited (Nomad and Joint Broker)
 Nick Athanas / Piers Shimwell (Corporate Finance)  Tel: +44 (0) 20 3328 5656

 Amrit Nahal / Matt Butlin (Sales & Broking)

 SI Capital Ltd (Joint Broker)
 Nick Emerson                                       Tel: +44 (0) 1483 413 500
 Jon Levinson                                       Tel: +44 (0) 20 3871 4066

 

Notes for Editors

 

About Advanced Oncotherapy Plc www.avoplc.com (http://www.avoplc.com/)

 

Advanced Oncotherapy, a UK headquartered company with offices in London,
Geneva, The Netherlands and in the USA, is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced Oncotherapy's
team "ADAM," based in Geneva, focuses on the development of a proprietary
proton accelerator called, Linac Image Guided Hadron Technology (LIGHT).
LIGHT's compact configuration delivers proton beams in a way that facilitates
greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that
will enable them to treat cancer with innovative technology as well as
expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging
improvements in delivering proton therapy and actively seeks working
relationships with providers of these innovative technologies. Through these
relationships, the Company will remain the prime provider of an innovative and
cost-effective system for particle therapy with protons.

 

 

 

 1    Details of the person discharging managerial responsibilities
 a)   Name                                                         Michael Bradfield
 2    Reason for the notification
 a)   Position/status                                              Non-Executive Director
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Advanced Oncotherapy plc
 b)   LEI                                                          213800LUDHZOG3YT6C82
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary shares of 25p each in Advanced Oncotherapy plc

      Identification code                                          Identification code (ISIN) for Advanced Oncotherapy plc ordinary shares:
                                                                   GB00BD6SX109
 b)   Nature of the transaction                                    Purchase of shares
 c)   Price(s) and volume(s)                                       Price(s) - 12.975 pence; Volume (s) - 100,000

                                                                   Price(s) - 13.2125 pence; Volume (s) - 100,000

                                                                   Price(s) - 13.2125 pence; Volume (s) - 50,000

                                                                   Price(s) - 13.2125 pence; Volume (s) - 250,000
 d)   Aggregated information

      - Aggregated volume                                          500,000 shares

      - Price                                                      13.165 pence

 e)   Date of the transaction                                      29 December 2022
 f)   Place of the transaction                                     London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGCBDDDDXDGDG